Anti-Diabetic Therapy, Heart Failure and Oxidative Stress: An Update

Area of Science:

• Cardiology
• Endocrinology
• Pharmacology

Background:

• Diabetes mellitus (DM) and heart failure (HF) are prevalent chronic conditions impacting millions globally.
• Hyperglycemia in DM contributes to oxidative stress, worsening diabetes and its complications.
• Oxidative stress damages cellular components, leading to vascular dysfunction.

Purpose of the Study:

• To review existing literature on antidiabetic drugs for glycemic control in patients with heart failure and oxidative stress.
• To evaluate the cardiovascular effects and safety profiles of various antidiabetic medication classes in this population.

Main Methods:

• Literature review of studies on antidiabetic drugs in patients with DM, HF, and oxidative stress.
• Analysis of drug efficacy, glycemic control, and cardiovascular outcomes.
• Comparison of different drug classes, including metformin, thiazolidinediones, meglinitides, acarbose, insulin, DPP-4 inhibitors, SGLT2 inhibitors, and GLP-1 receptor agonists.

Main Results:

• Metformin shows minor benefits; thiazolidinediones increase HF risk and are not recommended.
• Limited evidence exists for meglinitides and acarbose.
• Insulin and DPP-4 inhibitors appear to have neutral cardiovascular effects.
• SGLT2 inhibitors demonstrate significant cardiovascular benefits, reducing mortality and HF hospitalizations.
• GLP-1 receptor agonists show potential benefits for HF patients, with SGLT2 inhibitors preferred in cases of chronic kidney disease.

Conclusions:

• SGLT2 inhibitors are highly beneficial for diabetic patients with heart failure, improving cardiovascular outcomes.
• GLP-1 receptor agonists are a potential alternative, but SGLT2 inhibitors are favored in patients with renal impairment.
• Further research is needed for some drug classes, but SGLT2 inhibitors and GLP-1 receptor agonists represent promising therapeutic options.